Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics reported FY2025 revenue of $8.5 million, driven by an upfront payment from partner LaunXP, compared to zero revenue in the prior year. The company narrowed its net loss to $10.9 million, a significant improvement from the previous year's loss of $53.9 million, following a 64% reduction in operating expenses. Clinically, the Phase 2 SPARTA study for vebreltinib has enrolled over 280 subjects, with an IND submission for accelerated approval in the U.S. anticipated in the first half of 2027.
Key figures
- Revenue
- 8.5 million
- Drug Name
- vebreltinib (APL-101)
- Phase Of Trial
- Phase 2
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.